Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.

NCT03188172 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.

NCT NCT03188172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03188172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.
Lead sponsor
University of Leeds
Phase
Phase 2
Overall status
Unknown status
Start date
September 28, 2017
Completion date
May 31, 2026
Enrollment
95 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma